<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04315558</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#20-000129</org_study_id>
    <nct_id>NCT04315558</nct_id>
  </id_info>
  <brief_title>Revefenacin in Acute Respiratory Insufficiency in COPD</brief_title>
  <acronym>RARICO</acronym>
  <official_title>Revefenacin in Acute Respiratory Insufficiency in COPD (RARICO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mylan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RARICO is a pragmatic, randomized, controlled, double-blinded, multi-center trial evaluating
      the safety and feasibility of nebulized revefenacin in comparison to nebulized ipratropium in
      patients with COPD and acute respiratory failure requiring invasive mechanical ventilation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To assess the efficacy of nebulized revefenacin in improving the lung mechanics of
      COPD patients with acute respiratory failure requiring invasive mechanical ventilation (MV),
      in comparison to a control group receiving the short-acting muscarinic antagonist
      ipratropium.

      Hypothesis: Revefenacin is as efficacious as ipratropium in improving the lung mechanics of
      COPD patients with acute respiratory failure.

      Study Design:

      RARICO is a pragmatic, randomized, controlled, double-blinded, multi-center trial evaluating
      the safety and feasibility of nebulized revefenacin in comparison to nebulized ipratropium in
      patients with COPD and acute respiratory failure requiring invasive mechanical ventilation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>pragmatic, randomized, controlled, double-blinded</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>blinded medication delivery</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in total inspiratory resistance Rstat at the time of drug trough</measure>
    <time_frame>7 days</time_frame>
    <description>Reduction in total inspiratory resistance across the airways and ventilator circuit measured by the change in Static Resistance (Rstat) at the time of drug trough</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in total inspiratory resistance Rdyn at the time of drug trough</measure>
    <time_frame>7 days</time_frame>
    <description>Reduction in total inspiratory resistance across the airways and ventilator circuit measured by the change in Dynamic Resistance (Rdyn) at the time of drug trough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Resistive pressure (Pres) at the time of drug trough</measure>
    <time_frame>7 days</time_frame>
    <description>Reduction in total inspiratory resistance across the airways and ventilator circuit measured by the change in Resistive pressure (Pres) at the time of drug trough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in total inspiratory resistance Rstat at the time of drug peak</measure>
    <time_frame>7 days</time_frame>
    <description>Reduction in total inspiratory resistance across the airways and ventilator circuit measured by the change in Static Resistance (Rstat) at the time of drug peak</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaCO2</measure>
    <time_frame>7 days</time_frame>
    <description>Arterial partial pressure of CO2 measured at the drug trough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory therapist time at bedside</measure>
    <time_frame>7 days</time_frame>
    <description>RT resource utilization as reflected in the total effective time spent at the bedside providing care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Length of stay</measure>
    <time_frame>Hospital stay, expected to be less than 28 days</time_frame>
    <description>Time spent in the ICU from the enrollment in the study through the same-stay discharge from the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days to day 28</measure>
    <time_frame>Hospital stay, expected to be less than 28 days</time_frame>
    <description>Time spent ventilator-free from the day of enrollment in the study through the same-stay discharge from the hospital</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory: Ventilator compliance analysis (ventilator dyssynchrony, pressure-volume curve analysis, expiratory flow curve analysis)</measure>
    <time_frame>7 days</time_frame>
    <description>Ventilator compliance analysis (ventilator dyssynchrony, pressure-volume curve analysis, expiratory flow curve analysis)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety: Paradoxical bronchospasm, Hypersensitivity reaction, Severe urinary retention not explained by other reasons, Severe constipation not explained by other reasons</measure>
    <time_frame>7 days</time_frame>
    <description>Number of episodes of paradoxical bronchospasm, Hypersensitivity reaction, Severe urinary retention not explained by other reasons, Severe constipation not explained by other reasons</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>COPD</condition>
  <condition>Acute Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Revefenacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Revefenacin will be delivered once daily via nebulizer. In order to allow for full blinding and steady Q6 hours regimen in control arm, at hours 6, 12 and 18 after the Revefenacin dose, nebulized normal saline will be delivered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ipratropium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nebulized ipratropium will be delivered via nebulizer Q6 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Revefenacin Inhalation Solution [Yupelri]</intervention_name>
    <description>nebulized drug comparison</description>
    <arm_group_label>Revefenacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipratropium Bromide</intervention_name>
    <description>nebulized drug comparison</description>
    <arm_group_label>Ipratropium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥ 40 years of age

          -  Acute respiratory failure requiring invasive mechanical ventilation

          -  Documented history of COPD based on spirometric evidence of FEV1/FVC&lt;70%

          -  Smoking history &gt;10 years (current or prior)

          -  Invasive mechanical ventilation for &lt; 48 hours

        Exclusion Criteria:

          -  Invasive mechanical ventilation for &gt; 48 hours

          -  Chronic invasive mechanical ventilation via tracheostomy. Patients with tracheostomy
             alone without chronic mechanical ventilation may be enrolled.

          -  Expected duration of mechanical ventilation &lt;24 hours

          -  Hypersensitivity to muscarinic antagonists

          -  Inability to tolerate albuterol

          -  Lack of documented COPD history

          -  For patients taking short- or long-acting muscarinic antagonists (SAMAs or LAMAs) at
             the time of screening, inability or unwillingness to undergo the SAMA or LAMA washout
             period (6 hours or 24 hours, respectively) prior to initiating study drug.

          -  Presence of ARDS or acute congestive heart failure

          -  Unwillingness or inability to remain on the study drug with for the duration of the
             study

          -  Unwillingness or inability to have open-label muscarinic antagonists withheld for
             duration of the study

          -  Unwillingness or inability to utilize the Puritan-Bennett 980 (PB980) ventilator

          -  Pulmonary comorbidities such as pneumothorax or pneumomediastinum that, in the opinion
             of the investigator or clinical team, can pose a risk to subject safety or interfere
             with the subject's ability to complete the study procedures.

          -  Documented restrictive lung disease or history of interstitial lung disease

          -  Actual body weight exceeding 1 kg per centimeter of height

          -  Pregnancy

          -  AST or ALT &gt; 3 times the upper limit of normal, or other clinically significant acute
             or chronic liver disease

          -  Known history of glaucoma

          -  Enrollment in other interventional clinical trial

          -  Moribund patient not expected to survive &gt;24 hours

          -  Decision to withhold life-sustaining treatment, except in those patients committed to
             full support except cardiopulmonary resuscitation

          -  Inability to obtain informed consent from patient or legally authorized representative
             (LAR)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor Z Barjaktarevic, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donald Tashkin, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leslie Cortes</last_name>
    <phone>3102063669</phone>
    <email>LeCortez@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria (Carmela) Granone, MD</last_name>
    <phone>3108255316</phone>
    <email>MGranone@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ronald Reagan Medical Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Marissa Dembek</last_name>
      <phone>310-825-2616</phone>
      <email>mdembek@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nida Qadir, MD</last_name>
      <phone>3108258599</phone>
      <email>nqadir@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nida Qadir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santa Monica UCLA</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Marissa Dembek</last_name>
      <phone>310-825-2616</phone>
      <email>mdembek@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gregory Bierer, MD</last_name>
      <phone>3104490939</phone>
      <email>gbierer@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gregory Bierer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Donohue JF, Kerwin E, Sethi S, Haumann B, Pendyala S, Dean L, Barnes CN, Moran EJ, Crater G. Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease. Respir Med. 2019 Jul;153:38-43. doi: 10.1016/j.rmed.2019.05.010. Epub 2019 May 23.</citation>
    <PMID>31150963</PMID>
  </reference>
  <reference>
    <citation>Ferguson GT, Feldman G, Pudi KK, Barnes CN, Moran EJ, Haumann B, Pendyala S, Crater G. Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials. Chronic Obstr Pulm Dis. 2019 Apr 9;6(2):154-165. doi: 10.15326/jcopdf.6.2.2018.0152. Epub 2019 Apr 9.</citation>
    <PMID>30974049</PMID>
  </reference>
  <reference>
    <citation>Donohue JF, Feldman G, Sethi S, Barnes CN, Pendyala S, Bourdet D, Crater G. Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials. Pulm Pharmacol Ther. 2019 Aug;57:101808. doi: 10.1016/j.pupt.2019.101808. Epub 2019 May 30.</citation>
    <PMID>31152911</PMID>
  </reference>
  <reference>
    <citation>Quinn D, Barnes CN, Yates W, Bourdet DL, Moran EJ, Potgieter P, Nicholls A, Haumann B, Singh D. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. Pulm Pharmacol Ther. 2018 Feb;48:71-79. doi: 10.1016/j.pupt.2017.10.003. Epub 2017 Oct 4.</citation>
    <PMID>28987804</PMID>
  </reference>
  <reference>
    <citation>Zieliński J. Effects of ipratropium bromide on pulmonary hemodynamics in COPD. Chest. 1995 Oct;108(4):1181-2.</citation>
    <PMID>7555146</PMID>
  </reference>
  <reference>
    <citation>Rezaie N, Shams-Hosseini NS, Kashanizadeh A, Karimi MA. Ipratropium bromide is more effective than Salmeterol - Fluticason combination on O2 saturation patients with COPD. J Res Med Sci. 2013 Aug;18(8):731.</citation>
    <PMID>24379853</PMID>
  </reference>
  <reference>
    <citation>Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. Cardiovascular events associated with ipratropium bromide in COPD. Chest. 2010 Jan;137(1):13-9. doi: 10.1378/chest.08-2367. Epub 2009 Apr 10.</citation>
    <PMID>19363211</PMID>
  </reference>
  <reference>
    <citation>Khan SY, O'Driscoll BR. Is nebulized saline a placebo in COPD? BMC Pulm Med. 2004 Sep 30;4:9.</citation>
    <PMID>15458566</PMID>
  </reference>
  <reference>
    <citation>Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, Tesoro EP, Elswick RK. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med. 2002 Nov 15;166(10):1338-44.</citation>
    <PMID>12421743</PMID>
  </reference>
  <reference>
    <citation>Breen D, Churches T, Hawker F, Torzillo PJ. Acute respiratory failure secondary to chronic obstructive pulmonary disease treated in the intensive care unit: a long term follow up study. Thorax. 2002 Jan;57(1):29-33.</citation>
    <PMID>11809986</PMID>
  </reference>
  <reference>
    <citation>Acute Respiratory Distress Syndrome Network, Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000 May 4;342(18):1301-8.</citation>
    <PMID>10793162</PMID>
  </reference>
  <reference>
    <citation>Maqsood MH, Rubab K, Maqsood MA. The Role of Revefenacin in Chronic Obstructive Pulmonary Disease. Cureus. 2019 Apr 10;11(4):e4428. doi: 10.7759/cureus.4428. Review.</citation>
    <PMID>31245215</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Igor Barjaktarevic, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Acute Respiratory failure</keyword>
  <keyword>Long acting muscarinic antagonist</keyword>
  <keyword>nebulizer</keyword>
  <keyword>mechanical ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

